Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHemostemix Inc

Hemostemix Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.055 CAD 0.01 ( 10.00%)
Last update at 2026-11-04T19:21:00Z
VOLUME
2000
Market Cap
11.31M

Momentum Score

…

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.06
Low
0.06
High
52 Week Price Range
0.06
Low
0.16
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Hemostemix Inc is a small-cap Canadian company on the TSXV that appears to focus on regenerative medicine and cellular therapies, but public disclosures are limited. Long-term growth may be driven by clinical progress, regulatory approvals, partnerships or licensing and eventual commercialization of any lead programs, which could support milestone-driven value creation.
Primary risks include early-stage development, limited public information and liquidity, need for additional financing, clinical and regulatory failure risk, and strong competition in regenerative medicine.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.59
ROE
-
Net Debt
4.23M
ROCE
111.13%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.62M -2.50M -4.75M -6.54M -7.77M
Net income -2.62M -2.50M -5.24M -6.29M -7.77M
Selling general administrative 1.90M 1.33M 3.95M 6.47M 6.81M
Selling and marketing expenses - 1.77M - - -
Gross profit - -0.00M - - -
Reconciled depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Ebit - -2.16M -4.58M - -4.88M
Ebitda - -2.16M -4.40M -6.53M -7.66M
Depreciation and amortization - 0.00M - - -
Operating income -1.98M -2.16M -4.58M -6.66M -7.47M
Other operating expenses - 2.16M - - -
Interest expense 0.62M 0.55M 0.35M 0.01M 0.11M
Tax provision - 0.00M 0.49M -0.26M -
Interest income - - - 0.07M -
Net interest income -0.63M -0.56M -0.35M -0.02M -0.11M
Income tax expense - -0.00M 0.49M - -
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.98M 2.16M 4.58M 6.66M 7.47M
Cost of revenue - 0.00M - - -
Total other income expense net -0.01M -0.35M 0.18M 0.14M -0.19M
Net income from continuing ops -2.62M -2.50M -5.24M -6.29M -7.77M
Net income applicable to common shares - - -5.24M -5.24M -7.77M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.99M 0.31M 0.47M 0.56M 2.32M
Intangible assets 0.00M 0.00M - - 0.00M
Other current assets - 0.13M - - -
Total liab 8.20M 7.68M 7.23M 5.85M 3.42M
Total stockholder equity -7.20M -7.37M -6.77M -5.28M -1.10M
Other current liab - - - 1.04M 1.24M
Common stock - 42.48M 41.08M - 37.89M
Capital stock 43.92M 42.48M 41.08M 38.67M 37.89M
Retained earnings -65.88M -63.27M -60.76M -55.53M -49.24M
Other liab - - 0.49M - -
Cash 0.71M 0.16M 0.14M 0.22M 0.26M
Total current liabilities 2.77M 2.88M 2.62M 4.37M 3.42M
Net debt 4.23M 4.17M 3.99M 1.26M -
Short long term debt - - - - 0.17M
Short long term debt total - 4.32M - - -
Other stockholder equity - 11.93M 2.67M - 1.54M
Property plant equipment - - 0.00M - 0.00M
Total current assets 0.99M 0.31M 0.46M 0.56M 2.32M
Net tangible assets - - -6.77M - -1.10M
Net receivables - 0.03M 0.14M - 2.06M
Long term debt 4.94M 4.32M 4.13M 1.48M -
Accounts payable 2.77M 2.88M 2.62M 3.31M 1.98M
Accumulated other comprehensive income - 1.49M - - -
Non currrent assets other - 0.00M - - -
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments - - 0.00M 0.17M 0.00M
Change to liabilities - - -1.72M 0.00M 1.16M
Net borrowings - 0.00M 2.75M 2.75M -1.85M
Total cash from financing activities 2.45M 1.52M 6.02M 6.02M 6.21M
Change to operating activities - - 0.01M 0.01M -1.96M
Net income -2.62M -2.50M -5.24M -6.29M -7.77M
Change in cash 0.55M 0.02M -0.08M -0.08M 0.23M
Begin period cash flow 0.16M 0.14M 0.22M 0.26M 0.02M
End period cash flow 0.71M 0.16M 0.14M 0.22M 0.26M
Total cash from operating activities -1.90M -1.50M -6.10M -6.10M -5.98M
Issuance of capital stock 2.45M 1.50M 3.45M 0.84M 8.77M
Depreciation 0.00M 0.00M 0.00M 0.00M 0.00M
Change to account receivables - 0.11M - - -0.03M
Other cashflows from financing activities - -0.08M -0.20M -0.20M -0.71M
Change to netincome - - 0.84M 0.84M 2.62M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital -0.23M 0.55M -1.71M 2.82M -0.83M
Stock based compensation 0.33M 0.15M 0.18M 0.36M 2.32M
Other non cash items 0.62M 0.34M 0.35M 0.02M 0.11M
Free cash flow -1.90M -1.50M -6.10M -3.48M -5.98M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
HEM
Hemostemix Inc		 0.01
10.00%		 0.06 - - - 27.76 -4.37
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 -
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26 -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 -58.16

Profile*

Hemostemix Inc

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

707-7th Avenue SW, Calgary, AB, Canada, T2P 3H6

905-580-4170

https://hemostemix.com

Name Title Year Born
Mr. Thomas A. Smeenk B.A., BA Hons Co-Founder, Pres, CEO & Director 1962
Ms. Christina Wu CPA Interim Chief Financial Officer NA
Cameron Cole Head of Investor Relations NA
Dr. Fraser C. Henderson Sr., M.D. Chief Medical Officer NA
Mr. Thomas Abraham C.A. Pres of PreCerv Inc. NA
Mr. Thomas A. Smeenk B.A., BA Hons Co-Founder, President, CEO & Director 1962
Mr. Peter Pavlin Vice President of Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…